Current Report Filing (8-k)
October 03 2017 - 5:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
October 3, 2017
AYTU
BIOSCIENCE, INC.
|
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
Delaware
|
000-53121
|
47-0883144
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
373 Inverness Parkway, Suite 206, Englewood, Colorado
|
80112
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code:
(720) 437-6580
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
As previously disclosed in a current report
on Form 8-K filed on August 16, 2017, Aytu BioScience, Inc. (the “Company”) entered into a Securities Purchase Agreement
with various investors pursuant to which the Company sold Class A and Class B equity units for gross proceeds of approximately
$11.8 million. The offering closed on August 15, 2017.
Attached hereto as Exhibit 99.1 is a proforma
balance sheet as of June 30, 2017 giving effect to the closing and receipt by the Company of the gross proceeds of the offering.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 3, 2017
|
AYTU BIOSCIENCE, INC.
|
|
|
|
By:
|
/s/ Gregory A. Gould
|
|
|
Name: Gregory A. Gould
Title: Chief Financial Officer
|
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Mar 2024 to Apr 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2023 to Apr 2024